Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-IgE for chronic asthma.

S Walker1, M Monteil, K Phelan

  • 1National Respiratory Training Centre, The Athenaeum, 10 Church Street, Warwick, UK, CV34 4AB.

The Cochrane Database of Systematic Reviews
|August 15, 2003
PubMed
Summary

Omalizumab effectively reduced free immunoglobulin E (IgE) and helped patients decrease or stop corticosteroid use. This anti-IgE therapy also reduced asthma exacerbations in allergic asthma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HME coupled with FDM 3D printing of a customized oral solid form to treat pediatric epilepsy.

International journal of pharmaceutics·2025
Same author

Regulations on excipients used in 3D printing of pediatric oral forms.

International journal of pharmaceutics·2024
Same author

Disease burden, comorbidities and antecedents of chronic cough phenotypes in Australian adults.

Pulmonology·2023
Same author

Preclinical interstitial lung disease in relatives of familial pulmonary fibrosis patients.

Pulmonology·2022
Same author

DNA methylation epi-signature is associated with two molecularly and phenotypically distinct clinical subtypes of Phelan-McDermid syndrome.

Clinical epigenetics·2021
Same author

Mould-sensitized adults have lower Th2 cytokines and a higher prevalence of asthma than those sensitized to other aeroallergens.

Allergy·2016

Area of Science:

  • Immunology
  • Allergology
  • Pharmacology

Background:

  • Omalizumab is a monoclonal antibody targeting immunoglobulin E (IgE).
  • It inhibits IgE's role in allergic inflammation by preventing binding to effector cells.
  • Omalizumab-IgE complexes are small and do not appear to cause immune complex pathology.

Purpose of the Study:

  • To evaluate the efficacy of anti-IgE therapy in patients with allergic asthma.
  • To determine if anti-IgE treatment aids in reducing corticosteroid dependency.
  • To assess the impact of anti-IgE on asthma exacerbation rates.

Main Methods:

  • Systematic review of randomized control trials (RCTs) identified via Cochrane Airways Group Asthma trials register.
  • Included RCTs examined anti-IgE (Omalizumab) administered via various routes (inhaled, intravenous, subcutaneous).

Related Experiment Videos

  • Data extraction and quality assessment by two independent reviewers; subgroup analysis by asthma severity.

    • Main Results:

    • Eight trials involving 2037 participants showed Omalizumab significantly reduced free IgE by 98-99%.
    • Patients receiving Omalizumab had significantly higher odds of reducing or withdrawing inhaled corticosteroids.
    • Omalizumab treatment was associated with a reduced likelihood of asthma exacerbations.

    Conclusions:

    • Omalizumab is more effective than placebo in enabling patients to reduce or stop inhaled steroids.
    • The therapy is effective in decreasing asthma exacerbations and is generally well-tolerated.
    • Further research is needed in pediatric and severe adult populations, and direct comparisons with inhaled corticosteroids are warranted.